GET DAILY SIGNALSWhy Is Vericel Corporation (VCEL) Stock Up +11.92% Today?
Key Takeaways
- Vericel Corporation (VCEL) climbed roughly 11.92% on Thursday, November 5, 2026, after reporting third-quarter results that beat expectations.
- The primary catalyst was an earnings-driven move: Q3 EPS of $0.27 crushed the $0.06 consensus, and revenue of $85.4 million topped estimates of roughly $78 million.
- Management raised full-year 2026 revenue guidance for the third consecutive quarter, lifting the midpoint above analyst consensus.
- Secondary drivers included record MACI and burn-care revenue, a 179% jump in net income, and continued share repurchases.
- The advance extended a strong prior session, when the stock rallied more than 10% into the earnings release.
- Traders are now watching fourth-quarter MACI momentum, the 2027 MACI UK launch timeline, and follow-through analyst estimate revisions.
- For more detail, explore Price Targets, Earnings, and Forecast pages for VCEL.
- To see how AI-driven strategies are trading names like this one, visit Trending AI Robots.
Opening Summary
Vericel Corporation (VCEL), a commercial-stage regenerative medicine company focused on advanced cell therapies for sports medicine and severe burn care, surged in Thursday's session as investors digested a beat-and-raise quarterly report. The company's flagship product, MACI, treats cartilage defects in the knee, while its burn-care franchise includes Epicel and NexoBrid. Shares rose 11.92%, with the latest price around $50.90 versus a prior closing price of $45.48. Markets attributed the rally directly to third-quarter 2026 results released before the open, which exceeded profit and revenue forecasts and came alongside an upward revision to full-year guidance.
Q3 Earnings Beat and Raised Guidance
The dominant catalyst for the share-price rally was a sharply better-than-expected third quarter. VCEL posted adjusted diluted earnings of $0.27 per share, well above the consensus estimate of $0.06, while revenue of $85.4 million climbed 26% year over year and surpassed the roughly $78 million analysts had modeled. GAAP net income rose 179% to $14.2 million, underscoring a rare combination for a small-cap biotech of high growth and genuine profitability.
Just as important, management lifted its full-year 2026 revenue outlook to $344 million–$346 million, up from a prior range of $330 million–$340 million and above the consensus near $336 million. The guidance raise marked the third consecutive quarter of upward revisions, reinforcing investor confidence that demand momentum is durable rather than a one-time beat.
Product Momentum Across MACI and Burn Care
Beneath the headline numbers, growth was broad-based. MACI revenue rose 21% to $67.4 million, extending a streak of 20%-plus growth, while the burn-care segment delivered a record $18 million, up 52%. Epicel revenue increased 23% to $12.7 million, its highest quarterly figure since launch, and commercial NexoBrid revenue climbed 54% year over year. Gross margin of more than 73% and an adjusted EBITDA margin of roughly 30% both came in above guidance, while the company ended the quarter with about $236 million in cash and no debt and repurchased shares under its buyback authorization.
Market Context and Trading Activity
The stock's advance followed an already strong prior session, when VCEL rose more than 10% as investors positioned ahead of the report. Trading volume during the move was elevated relative to recent sessions, consistent with an event-driven, earnings-fueled repricing. The rally pushed shares to levels approaching the upper end of their 52-week range and well beyond recent trading levels, reflecting a technical breakout driven by fundamental news rather than broad sector rotation. While the biotechnology and medical-technology complex has been mixed in recent sessions, VCEL's move was largely idiosyncratic, tied to its own results and guidance rather than a sweeping market-wide catalyst.
What Comes Next for VCEL
Looking ahead, investors will focus on whether MACI can sustain its 20%-plus growth into the fourth quarter, where management now expects roughly $102 million in revenue at the midpoint. Additional watch points include the planned MACI launch in the United Kingdom in the second half of 2027, ongoing expansion of NexoBrid adoption across burn centers, and the company's ability to continue widening margins. Risks include potential quarterly lumpiness in surgical procedure volumes, the timing of procurement revenue, and competitive and reimbursement dynamics. Analyst estimate revisions following the strong report will be closely monitored as a gauge of how much of the upside is now reflected in the stock.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of systematic approaches to consider. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VCEL in upward trend: price rose above 50-day moving average on November 03, 2026
VCEL moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 50 of 60 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 71 cases where VCEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCEL as a result. In 80 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for VCEL just turned positive on November 04, 2026. Looking at past instances where VCEL's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
The 10-day moving average for VCEL crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +12.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCEL advanced for three days, in 218 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 164 of 225 cases where VCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
VCEL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. VCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.294) is normal, around the industry mean (2.904). VCEL has a moderately high P/E Ratio (92.816) as compared to the industry average of (-0.738). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (6.887) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of patient-specific expanded cellular therapies for use in the treatment of patients with diseases
Industry Biotechnology
Advertisement